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Abstract
Background: In our previous studies, we have demonstrated that insulin-like growth factor binding protein-related
protein1 (IGFBP-rP1) played its potential tumor suppressor role in colon cancer cells through apoptosis and
senescence induction. In this study, we will further uncover the role of IGFBP-rP1 in colon cancer differentiation
and a possible mechanism by revealing responsible genes.
Results: In normal colon epithelium, immunohistochemistry staining detected a gradient IGFBP-rP1 expression along
the axis of the crypt. IGFBP-rP1 strongly expressed in the differentiated cells at the surface of the colon epithelium,
while weakly expressed at the crypt base. In colon cancer tissues, the expression of IGFBP-rP1 correlated positively
with the differentiation status. IGFBP-rP1 strongly expressed in low grade colorectal carcinoma and weakly expressed
in high grade colorectal carcinoma. In vitro, transfection of PcDNA3.1(IGFBP-rP1) into RKO, SW620 and CW2 cells
induced a more pronounced anterior-posterior polarity morphology, accompanied by upregulation with alkaline
phosphatase (AKP) activity. Upregulation of carcino-embryonic antigen (CEA) was also observed in SW620 and CW2
transfectants. The addition of IGFBP-rP1 protein into the medium could mimic most but not all effects of IGFBP-rP1
cDNA transfection. Seventy-eight reproducibly differentially expressed genes were detected in PcDNA3.1(IGFBP-rP1)-
RKO transfectants, using Affymetrix 133 plus 2.0 expression chip platform. Directed Acyclic Graph (DAG) of the
enriched GO categories demonstrated that differential expression of the enzyme regulator activity genes together
with cytoskeleton and actin binding genes were significant. IGFBP-rP1 could upreguate Transgelin (TAGLN),
downregulate SRY (sex determining region Y)-box 9(campomelic dysplasia, autosomal sex-reversal) (SOX9), insulin
receptor substrate 1(IRS1), cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4) (CDKN2B), amphiregulin
(schwannoma-derived growth factor) (AREG) and immediate early response 5-like(IER5L) in RKO, SW620 and CW2
colon cancer cells, verified by Real time Reverse Transcription Polymerase Chain Reaction (rtRT-PCR). During sodium
butyrate-induced Caco2 cell differentiation, IGFBP-rP1 was upregulated and the expression showed significant
correlation with the AKP activity. The downregulation of IRS1 and SOX9 were also induced by sodium butyrate.
Conclusion: IGFBP-rP1 was a potential key molecule associated with colon cancer differentiation. Downregulation
of IRS1 and SOX9 may the possible key downstream genes involved in the process.
Introduction
Insulin-like growth factor binding proteins (IGFBPs),
described as essential modulators of IGF bioavailability,
are a family of homologous proteins produced by many
different tissues. IGFBPs have different molecular
weight, amino acid composition, binding properties and
distribution in biological fluids [1,2]. The classified
IGFBPs, including IGFBP1-6, cooperate in regulating
signals from insulin receptors and IGF receptors. The
last few years have brought complexity, but also new
vistas of insights into the IGFBPs superfamily with dis-
covery of new IGFBPs(IGFBP7-15), who exhibit a low
affinity for IGF. These IGFBPs were reclassified as
IGFBP-related proteins (IGFBP-rPs), whose roles in
intracellular signaling, cell growth and cell metabolism
are emerging [3,4].
IGFBP-rP1 has been independently cloned in several
cellular systems, and therefore has been previously iden-
tified as IGFBP7[4], meningioma associated cDNA 25
(mac25) [5,6], tumor-derived adhesion factor(TAF) [7],
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was cloned as a gene that downregulated in meningioma
cell lines compared to primary cultures of benign lepto-
meningeal cells and as a senescence-associated gene
from human mammary epithelial cells [5]. IGFBP-rP1 is
particularly intriguing due to its implicated role in can-
cer. In vivo, different expression patterns of IGFBP-rP1
were found in various tumor types. Upregulated expres-
sion of IGFBP-rP1 was observed in acute lymphoblasma
leukemia and in thyroid cancer [9,10]. Downregulated
expression of IGFBP-rP1 was common in liver cancer,
lung cancer and in meningiomas [11-13]. While both
up- and downregulation of IGFBP-rP1 have been
reported in breast and prostate cancer [14-17]. These
findings make the role of IGFBP-rP1 complicated. In
1999, our laboratory purified the cDNA fragments of
IGFBP-rP1 from colonic adenocarcinoma and normal
mucosa cDNA subtraction libraries by suppressive sub-
tractive hybridization (SSH) [18]. Our group presented
evidence that methylation of exon 1 was the key
regulatory mechanism silencing the expression of
IGFBP-rP1 in colon cancer cell lines [19]. IGFBP-rP1
suppressed the proliferation, decreased the colony for-
mation ability, and induced apoptosis and senescence
in colorectal cancer cell lines [20,21]. The expression
of IGFBP-rP1 was correlated with favourable prognosis
in colon cancer patients[20]. All these findings strongly
supported that IGFBP-rP1 played a potential tumor
suppressor role against colorectal carcinogenesis. The
tumor suppressive role of IGFBP-rP1 was also found in
other types of cancer, including cervical cancer [22],
osteosarcoma [22,23], prostate cancer [14,24], breast
cancer [25], lung cancer[13], melanoma [26]and thyr-
oid cancer[10].
The balance among proliferation, differentiation,
senescence and apoptosis is tightly regulated to maintain
homeostasis of colon epithelium. Neoplastic transforma-
tion arises from multiple defects in these processes.
Malignant transformation is often characterized by both
deregulated cell cycle, increased cell survival and loss of
differentiation [27,28]. However, the role of IGFBP-rP1
in the differentiation in colon cancer cells remains elu-
sive. The objectives of the present work were to uncover
the role of IGFBP-rP1 in the differentiation of colon
cancer and its possible responsible genes.
Materials and methods
Reagents
Dulbecco’s Modified Eagle’s Medium (DMEM) was pur-
chased from GIBCO Laboratories (Grand Island, NY,
USA). Fetal bovine serum (FBS) was purchased from
HyClone Laboratories (Logan, UT, USA). Polyfect trans-
fection reagent and RNeasy mini kit was purchased
from QIAGEN (Hilden, Germany). G418 was purchased
from Merck (Darmstadt, Germany). Trizol reagent was
purchased from Invitrogen (Carlsbad, CA, USA). The
polyclonal antibody of IGFBP-rP1 and of Actin were
purchased from Santa Cruz Biologicals (CA, USA).
The monoclonal antibody of IGFBP-rP1 and the recom-
binant IGFBP-rP1 protein were purchased from RD
(Minneapolis, MN USA). The monoclonal antibody of
carcinoembryonic antigen (CEA) and polyclonal anti-
body of caudal-related homeodomain transcription 2
(CDX2) were purchased from Cell Signaling (Danvers,
MA, USA). Horseradish peroxidase-conjugated second-
ary antibodies were purchased from Zymed (San Fran-
cisco, CA, USA). Sodium Butyrate was purchased from
Sigma Chemical Company (St. Louis, MO, USA). An
alkaline phosphatase (AKP) kit was purchased from
Pointe Scientific Inc.(Canton, MI, USA).
Tissues
All 221 patients with colorectal carcinoma, 121 males
and 100 females, were inhabitants of Xiaoshan District,
Zhejiang Province, China. The age range of the patients
was from 26 to 85 years (median, 59 years). All archival
paraffin-embedded tissue blocks were collected from the
Department of Pathology, Zhejiang University, and the
People’s No. 1 Hospital of Xiaoshan, and the Zhejiang
Cancer Hospital from January 1990 to December 2000.
Patient and treatment data were collected from patient
records. The 221 patients had not received chemother-
apy or radiotherapy prior to surgery. Paraffin-embedded
tissue blocks were processed according to standard his-
tologic procedures and stained with H&E. The type of
histology: tubular adenocarcinoma (n = 164), papillary
adenocarcinoma (n = 26), mucinous adenocarcinoma
(n = 27), ring cell carcinoma, and undifferentiated carci-
noma (n = 4), assessed by two experienced pathologists.
Immunohistochemisty
The immunohistochemical staining was carried out as
described[20]. Paraffin-embedded sections (5 μmt h i c k )
were first dewaxed in xylene and rehydrated with a
graded ethanol series. Endogenous peroxidase was
quenched by incubation in 3% H2O2 for 10 min at room
temperature. Nonspecific binding was blocked by incu-
bation in a 1:10 dilution of rabbit serum for 30 min at
room temperature. Then, sections were incubated at 4°C
overnight with a 1:200 dilution of goat polyclonal anti-
body against human IGFBP-rP1. After several washes in
PBS, the sections were incubated with a 1:200 dilution
of biotinylated rabbit IgG at room temperature for 30
min. Then, the slides were incubated in a 1:200 dilution
of rabbit horseradish peroxidase at room temperature
for 20 min. The peroxidase activity was visualized by
incubating in 0.06% 3-3’-diaminobenzidine-H2O2.T h e
sections were finally counter stained with hematoxylin.
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pendently scored by two pathologists.
Cell lines
Human colorectal carcinoma RKO, SW620, CW2 and
Caco2 cell lines were maintained in DMEM supplemen-
ted with 10% FBS in a 37°C/5% CO2 atmosphere.
PcDNA3.1(IGFBP-rP1)-RKO, PcDNA3.1(IGFBP-rP1)-
SW620, PcDNA3.1(IGFBP-rP1)-CW2 transfectants and
the empty vector transfectants were established as pre-
viously described [20,21], maintained in the same cul-
ture medium containing 200 μg/ml G418.
Recombinant IGFBP-rP1 stimulation assay
R K O ,S W 6 2 0a n dC W 2c e l l sw e r es e e d e di n t o6 - w e l l
plate at 2 × 10
5 cells/plate, 4 × 10
5 cells/plate, 4 × 10
5
cells/plate, respectively. After attachment for 24 hr, the
cells were replaced by free culture medium with recom-
binant IGFBP-rP1 protein (For RKO cells, 10 μg/ml, For
SW620 and CW2 cells, 4 μg/ml). Forty-eight hours after
IGFBP-rP1 addition, cell morphology was observed and
photographed. Expression of differentiation markers
were performed on the cell lysates and supernatants.
AKP activity assays
Cell lysates and the supernatants of the PcDNA3.1
(IGFBP-rP1) transfectants, PcDNA3.1 transfectants, par-
ental cells, and cells stimulated with recombinant
IGFBP-rP1 protein were harvested as discussed above.
AKP activity was determined according to the protocol
of the kit. P-nitrophenyl phosphate disodium hexahy-
drate was used as a substrate. Synthetic alkaline phos-
phatase was used to construct a standard dilution curve.
Western Blot
Antibodies directed against actin (1:5000), CEA (1:1000),
CDX2 (1:1000) were used in Western blot analyses. Cell
lysates (50 μg) were resolved in prepoured Tris-glycine
SDS gels (Bio-Rad, Richmond CA), and transferred to a
nitrocellulose membrane (Bio-Rad). Blots were blocked
in 5% nonfat milk in TBST (TBS buffer containing 0.1%
tween), incubated with the primary antibody overnight
at 4°C, washed in TBST, and then incubated with appro-
priate secondary antibody for 1 hr at room temperature.
Antibody binding was detected using enhanced chemilu-
minescence reagent according to the manufacturer’s
instructions.
RNA isolation and microarray hybridization
We applied Affymetrix HG133 plus 2.0 chip to detect
differentially expressed genes transfected by PcDNA3.1
(IGFBP-rP1) in RKO cells. As technical replication of
Affymetrix chip were more than 99% consistent, we
performed biological replications to reduce sampling
variability. We selected three single-cell clones of
PcDNA3.1(IGFBP-rP1) transfectants, identified as RP5,
RP6, RP7, also three control vector transfectants as
control, named as EV5, EV6, EV7. Cells were divided
into three paired groups, RP5 VS EV5, RP6 VS EV6,
RP7 VS EV7. The paired cells were cultured in the
same condition and harvested at the same time to
minimize gene expression changes due to cell culture
conditions. Total RNA was isolated from cells using
RNeasy mini kit (Qiagen, Germany). RNA was quanti-
tated by UV absorbance at 260 and 280 nm and
assessed qualitatively using an RNA LabChip and Bioa-
nalyzer 2100 (Agilent, Palo Alto, CA). To generate a
biotinylated probe, cDNA was synthesized (Superscript
cDNA synthesis kit, Invitrogen, San Diego, CA) from 4
μg RNA using an oligo(dT) primer with a T7 RNA
polymerase promoter at the 5’ end. The cDNA was
m a d ed o u b l es t r a n d e da n du s e di na ni nv i t r ot r a n -
scription reaction (Enzo Diagnostics) with T7 RNA
polymerase to synthesize biotinylated product for
hybridization to Affymetrix GeneChips HU133 plus 2.0
using the Affymetrix recommended protocolhttp://
www.affymetrix.com/support/technical/manual/expres-
sion_manual.affx. Human HG-U133 plus 2.0 chips
(Affymetrix, Inc.) were hybridized with 15 μgo ff r a g -
mented labeled cRNA overnight at 45°C, washed (Gen-
echip Fluidics Station 400; Affymetrix), and scanned
(GeneArray Scanner; Affymetrix) according to Affyme-
trix protocols. Together 6 chips were performed.
Microarray data analysis
Scanned images of microarray chips were analysed by
the GeneChip Operating Software (GCOS1.2) from
Affymetrix. The total HG-U133 Plus 2 signal was nor-
malized to an arbitrary signal intensity value of 500. Dif-
ferentially expressed genes between IGFBP-rP1
transfectants and the controls in the groups were identi-
fied using the GCOS change algorithm and Rank Pro-
ducts (RP) following RMA (Robust Multiarray Analysis,
One-sided Wilcoxon’s Signed Rank Test). A total of
t h r e ep o s s i b l ep a i r w i s ec o m parisons were conducted
(RP5 VS EV5, RP6 VS EV6, RP7 VS EV7). For each
comparison between the groups, the number of increase
and decrease calls of each probe set was calculated
using MS Excel and probe sets with the highest number
of consistent changes among all samples were identified.
Using these criteria, 115 genes showed statistically sig-
nificant alterations in expression in at least two replicate
studies. Gene lists were uploaded to GOTM, and func-
tional annotation was performed. Further information
on genes were obtained from public databases, such as
NCBI. Hierarchical clustering was done using the clus-
tering function (condition tree) in GeneSpring7.2 (Sili-
con Genetics, Inc., Redwood City, CA).
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Three micrograms of total RNA was reverse transcribed
by M-MuLV reverse transcriptase with Oligo(dT)16 as a
primer. RtRT-PCR was performed on the ABI PRISM
7500 sequence detection system (Applied Biosystems,
Foster City, CA, USA) by monitoring the increase of
fluorescence by the binding of SYBR Green (Applied
Biosystems) to double-stranded DNA. Dissociation ana-
lysis was performed at the end of each PCR reaction to
ensure there was only specific product. Settings for the
PCR thermal profile were: initial denaturation at 95°C
for 1 min, followed by 40 amplification cycles of 95°C
for 15 sec, annealing at 59°C for 20 sec, and elongation
at 72°C for 40 sec. The primer sequences used are listed
in Table 1. Each PCR was run in triplicate. For quantifi-
cation of gene expression changes,
the ΔΔCt method was
used to calculate relative -fold changes normalized
against the GAPDH gene.
Cell differentiation induction assays
For sodium butyrate treatments, Caco2 cells were
seeded into 60-mm culture dishes at 3 × 10
5 cells/plate.
After 24 hr, cells were cultured in medium contained 4
mmol/L sodium butyrate. The cells were harvested at
the time points of 24 hr, 48 hr, 72 hr after sodium buty-
rate stimulation. Expression of differentiation markers
and IGFBP-rP1 were performed in the cell lysates and
supernatants.
ELISA
The ELISA method was carried out as described [34].
Briefly, wells of microtiter plates were coated (for 18 hr
at 4°C) with 100 ng/ml IGFBP-rP1 polyclonal antibody
in 100 μlo fc o a t i n gb u f f e r( 0 . 0 5MN a 2CO3 and 0.05 M
NaHCO3, pH 9.6) and were then blocked with 2% BSA
in PBS for 1 hr at 37°C. Samples were diluted with 0.5%
BSA (1:1) and a total of 100 μl was loaded in duplicates
and incubated for 2 hr at room temperature, followed
by the addition of 100 μl IGFBP-rP1 monoclonal anti-
body (200 ng/ml) for an additional 2 hr at room tem-
perature. HRP-conjugated goat anti- mouse IgG
(1:20,000) in blocking buffer was added (for 1 hr at
room temperature) and the reaction was visualized by
the addition of 100 μl of the chromogenic substrate
(3,30,5,50- tetramethylbenzidine) for 30 min. The reac-
tion was stopped with 100 μlH 2SO4 and absorbance at
450 nm was measured with a reduction at 630 nm using
ELISA plate reader. Plates were washed five times with
washing buffer (PBS, pH 7.4, containing 0.1% (v/v)
Tween 20) after each step. As a reference for quantifica-
tion, a standard curve was established by a serial dilu-
tion of recombinant IGFBP-rP1 protein, ranging from
150 ng/ml to 1 ng/ml.
Statistical analysis
Statistical package SPSS (version 11.0) was applied. The
Chi-square test was used to analyze the ranked data in
tissue samples. Student’t test was used in the cell line
experiments. A value of P < 0.05 was considered statisti-
cally significant.
Results
Expression pattern of IGFBP-rP1 in normal colonic
epithelium and colorectal carcinoma
The expression pattern of IGFBP-rP1 in the human
colonic epithelium was analyzed using immunohisto-
chemistry staining. The intensity of IGFBP-rP1 staining
varied from the basal compartment to the surface
epithelium. Epithelial cells at the surface displayed a
very strong IGFBP-rP1 expression, whereas IGFBP-rP1
staining was much weaker at the crypt base (Figure 1A).
These results indicated that IGFBP-rP1 expression is
stronger in the proliferating and differentiating
Table 1 Primer sequences used in rtRT-PCR
Gene Primer Product
(bp)
Design
AREG 5’ CGGGAGCCGACTATGACTACTC 3’
5’ GGGCTTAACTACCTGTTCAACTCTG 3’
100 [29]
IRS1 5’CAGAGGACCGTCAGTAGCTCAA 3’
5’GGAAGATATGAGGTCCTAGTTGTGAAT3’
135 [29]
CDKN2B 5’CACCGTTGGCCGTAAACTTAAC 3’
5’TAATGAAGCTGAGCCCAGGTCT 3’
96 [30]
ID1 5’ ATTTCTTCTCGTTTTCACAGGC 3’
5’ TCGGTCTTGTTCTCCCTCAG 3’
174 [31]
SOX-9 5’AGGTGCTCAAAGGCTACGACT 3’
5’AGATGTGCGTCTGCTCCGTG3’
359 [32]
STC1 5’ AACCCTGAAGCCATCACTG 3’
5’ GCTTCGGACAAGTCTGTTATAG 3’
78 [33]
TACSTD1 5’TGTTTGGTGATGAAGGCAGA 3’
5’ ACGCGTTGTGATCTCCTTCT 3’
324 Primer
5.0
TAGLN 5’ATCCTGTCTGTCCGAACCC 3’
5’ GCACTATGATCCACTCCACC 3’
184 Primer
5.0
FRMD4A 5’ TGGCTTCTCACTTCAATCT 3’
5’ CCACGGGTCCTGACTTTT 3’
134 Primer
5.0
IER5L 5’ AGCCCTTGGAGCCTCTGCA 3’
5’ CGGAGCCAAAGATGGAGATCA 3’
214 Primer
5.0
SP140 5’ TGATCCTCCAAGAATACG 3’
5’ ACAAGTGTCGCAACAGAA 3’
141 Primer
5.0
SYN1 5’GTGTCAGGGAACTGGAAGACC 3’
5’TGAGCGGCATGGAGGAAC3’
192 Primer
5.0
LAMB1 5’ GAAGACGGGAAGAAAGGG 3’
5’ GTCGAGGTCACCGAAAGC 3’
245 Primer
5.0
KERATIN 7 5’ CAATGAGACGGAGTTGACAG 3’
5’ ACGCTGGTTCTTGATGTT 3’
304 Primer
5.0
KERATIN 8 5’ TTGCAGATGCCGAGCAGCGT 3’
5’ TGGGCTGAGGGCTAGGGCTG 3’
576 Primer
5.0
PROFILIN2 5’ ATTGTCGGCTACTGCG 3’
5’ ATTGTATGTTGGCTCC 3’
237 Primer
5.0
GAPDH 5’ ACGGATTTGGTCGTATTGGG 3’
5’ CGCTCCTGGAAGATGGTGAT 3
213 Primer
5.0
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IGFBP-rP1 expression is also well maintained in color-
ectal cancer. Comparison of the IGFBP-rP1 expression
level performed in paired cancerous and normal tissues
indicated that IGFBP-rP1 was overexpressed in colon
cancer tissue compared to paired normal tissue (P =
0.001, Table 2). When analysed the expression pattern
of IGFBP-rP1 in cancer we found that IGFBP-rP1 was
strongly expressed in the well differentiated colorectal
adenocarcinoma, while weakly expressed in poorly dif-
ferentiated colorectal adenocarcionma (Figure 1B-D).
We then analyzed the correlation between the expres-
sion of IGFBP-rP1 and the differentiation status of the
colorectal carcinoma. The staining of IGFBP-rP1 was
divided into four grades (0-2), representing lack and
mild of staining (0), intermediate staining (1), and strong
staining (2). The histologic grade of colorectal
carcinoma was divided into two grades: low grade
(gland formation >50% in tubular adenocarcinoma and
papillary carcinoma) and high grade (gland formation
<50% in tubular adenocarcinoma, mucinous
A
C
B
D
Figure 1 IGFBP-rP1’s expression in normal colonic epithelium and primary colon cancer. Representative images of IGFBP-rP1 detection by
immunohistochemistry staining in human colonic tissue sections. Magnification: _200. A. IGFBP-rP1 expression localized to the terminally
differentiated epithelium at the luminal surface of the bowel and at the tops of the colonic crypts. B. Strong expression of IGFBP-rP1 in low
grade colorectal adenocarcinoma. C. Media expression of IGFBP-rP1 in medium grade colorectael adenocarcinoma. D. Weak expression of IGFBP-
rP1 in high grade colorectal adenocarcionma.
Table 2 Comparison of IGFBP-rP1’s expression in paired
cancerous and normal tissues
IGFBP-rP1
expression in
Cancerous tissue
IGFBP-rP1 expression in
paired Normal tissue
Total Significance
01 2
01 4 3 8
1 2 68 7 2 11 3 4
2 5 26 24 55
Total 32 117 48 197 0.001*
The staining of IGFBP-rP1 was divided into four grades (0-2), representing lack
and mild of staining (0), intermediate staining (1), and strong staining (2).
*The P value was calculated by McNemar-Bowker Test.
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Page 5 of 17adenocarcinoma, signet ring cell carcinoma, and undif-
ferentiated carcinoma). As a result, the higher expres-
sion of IGFBP-rP1 was closely related with good
differentiation status (Table 3). The difference was
found to be statistically significant (P = 0.006).
Morphology change of colorectal cancer cells induced by
IGFBP-rP1
Under light microscopy, we found that control vector
transfected RKO cells exhibited the same polygon-like
morphology as the parental RKO cells, while PcDNA3.1
(IGFBP-rP1)-RKO transfectants exhibited elongated
morphology with a more pronounced anterior-posterior
polarity. As in SW620 and CW2 cells, we found that the
parental and the control vector transfected cells exhib-
ited the round cell morphology, while PcDNA3.1
(IGFBP-rP1) transfectants were flatter and spindle
shaped. Similar morphological changes were seen when
recombinant IGFBP-rP1 protein was added into the cul-
ture medium of the parental cells (Figure 2).
Regulation of well known differentiation markers by
IGFBP-rP1
To further explore the role of IGFBP-rP1 in colon can-
cer differentiation, the expression level of several colonic
epithelial cell differentiation markers, including AKP
activity, CEA and CDX2, were determined. The experi-
ments were done in three colon cancer cell lines, RKO,
SW620 and CW2 cells. The PcDNA3.1(IGFBP-rP1)
transfectants showed increased AKP activity compared
with the empty vector transfectants and the parental
cells, in both the cell lysates and the supernatants of the
cells (Figure 3A). The differences were statistically sig-
nificant with p values < 0.05. PcDNA3.1(IGFBP-rP1)-
SW620 and PcDNA3.1(IGFBP-rP1)-CW2 transfectants
showed increased CEA expression, but no obvious regu-
lation on CDX2. As to RKO cells, no detectable regula-
tion of CEA but a little downregulation of CDX2 was
observed after transfection with IGFBP-rP1 cDNA
(Figure 3B). The addition of recombinant IGFBP-rP1 to
the superculture medium of the cells could mimic the
effects of the transfection of IGFBP-rP1, although the
extent was not that high (Figure 4).
Gene expression profiles
Microarray analysis was performed to analyze the gene
expression induced by IGFBP-rP1 in three PcDNA3.1
(IGFBP-rP1) clones and three control clones. The repro-
ducible 115 gene expression levels were used as a gene
list and experiments were organized by both individual
samples (to test sample reproducibility) as well as
groups (IGFBP-rP1 transfectants vs control) (Figure 5).
Collectively, seventy-eight genes reproducible in two
clones were identified. Based on the gene ontology clas-
sification and the information in PUBMED, we classified
the genes into 6 categories, including cytoskeleton and
actin binding, extracellular, cell proliferation and differ-
entiation, enzyme regulation, nuclear transcription, and
others. Quantitative data for the magnitude of each gene
expression change, together with gene descriptions are
shown in Table 4. We utilized the Directed Acyclic
Graph (DAG) of the enriched GO categories (Figure 6),
which demonstrated that enzyme regulator activity
genes, cytoskeletal proteins, and actin binding genes
showed the highest differential expression and signifi-
cance ((P < 0.01). Among them sixteen genes were
reproducible in 3 clones, including IGFBP-rP1, Transge-
lin (TAGLN), SP140 nuclear body protein (SP140),
FERM domain containing 4A (FRMD4A), caldesmon 1
(CALD1), neuron navigator 3 (NAV3), SRY (sex deter-
mining region Y)-box 9(campomelic dysplasia, autoso-
mal sex-reversal) (SOX9), stanniocalcin 1 (STC1),
amphiregulin(schwannoma-derived growth factor)
(AREG), inhibitor of DNA binding 1, dominant negative
helix-loop-helix protein (ID1), insulin receptor substrate
1 (IRS1), tumor-associated calcium signal transducer 1
(TACSTD), immediate early response 5-like (IER5L),
cyclin-dependent kinase inhibitor 2B (p15, inhibits
CDK4) (CDKN2B), synapsin I (SYN1) and laminin, beta
1 (LAMB1).
Validation of a Subset of the differentially expressed
genes by RT-PCR
To examine the reliability of the microarray data, the 16
reproducible genes in three clones, together with the
cytoskeletal protein binding genes and actin binding
genes keratin 7 (KRT7), keratin 8 (KRT8) and profilin2
(PFN2) were chosen for additional validation, by rtRT-
PCR(Figure 7). The Affymetrix chip data and the rtRT-
PCR data showed a good correlation. The relative fold
change for IGFBP-rP1 measured by rtRT-PCR is 2.1 ×
10
6 and 97 as measured by microarray chips. Eleven
transcripts examined (CALD, P15, FRMD4A, ID1, IRS1,
Table 3 Correlation between IGFBP-rP1 expression and
differentiation in colorectal carcinoma
IGFBP-rP1 expression Grade
a Total Significance
Low High
03 9 1 2
1 102 46 148
24 3 1 8 6 1
Total 148 73 221 0.006*
The staining of IGFBP-rP1 was divided into three grades (0-2), representing
lack and mild of staining (0), intermediate staining (1), and strong staining (2).
ahistologic grade: low grade (gland formation >50% in tubular
adenocarcinoma and papillary carcinoma) and high grade (gland formation
<50% in tubular adenocarcinoma, mucinous adenocarcinoma, signet ring cell
carcinoma, and undifferentiated carcinoma).*The P value was calculated by
chi-square test.
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strated concordant levels of differential expression
between GeneChip and RT-PCR analysis. Six additional
genes (AREG, KRT8, IER5L, PFN2, STC1, SYN1)
showed qualitatively concordant, but quantitatively dif-
ferent expression fold changes between gene chip and
RT-PCR analysis. One gene (KRT7) showed qualitatively
different expression fold changes. These difference are
more likely explained by the use of the
ΔΔCT method to
calculate relative expression levels in the RT-PCR assay.
To explore whether these differentially expressed genes
could also be induced by IGFBP-rP1 in other colon can-
cer cells, we analyzed the expression change of these
genes in PcDNA3.1(IGFBP-rP1)-SW620 and PcDNA3.1
(IGFBP-rP1)-CW2 transfectants. We found that IGFBP-
rP1 could upreguate TAGLN, downregulate SOX9,
I R S 1 ,P 1 5 ,A R E G ,I E R 5 L ,K R T 8i nt h e s ec o l o nc a n c e r
cells(Figure 8), indicating that these genes may be the
important IGFBP-rP1 responsible genes in colon cancer.
Gene expression changes during differentiation induced
by butyrate in Caco2 cells
The sodium butyrate induced Caco2 cell differentiation
model has been widely used. The phenomenon was also
verified in our study. After 72 hr stimulation, the signifi-
cant upregulation of AKP activity and CEA expression
confirmed that differentiation occurred (Figure 9A, B).
Loss of cell membrane integrity and loss of cell attach-
ment were observed at the 72 hr stimulation point (Fig-
ure 9C), although there is no detectable morphology
change at the 24 hr and 48 hr stimulation point. We
want to use this model to study the IGFBP-rP1 regula-
tion in this differentiation process. We found that
IGFBP-rP1 protein increased during sodium butyrate-
induced terminal cell differentiation (Figure 9D). The
IGFBP-rP1 expression level showed consistent correla-
tion with the AKP activity during the differentiation
process, at 24 hr, 48 hr, 72 hr time points of the sodium
butyrate stimulation (Figure 9E). We then performed
RKO-bl RKO-ev RKO-rp RKO-pr
SW620-bl SW620-ev SW620-rp SW620-pr
CW2-bl CW2-ev CW2-rp CW2-pr
Figure 2 Morphology of IGFBP-rP1 expressed cells and the control cells . Three colon cancer cell lines (RKO, SW620, CW2) were cultured in
DMEM medium. Phase-contrast micrographs of various cells were photographed. A, Parental blank cells (-bl). B, Cells transfected with PcDNA3.1
empty vector (-ev). C, Cells transfected with PcDNA3.1(IGFBP-rP1) (-rp). D, Cells treated with recombinant IGFBP-rP1 protein for 48 hr (-pr, 4 μg/ml
for SW620 and CW2, 10 μg/ml for RKO,). RKO cells, Magnification: 100. SW620, CW2 cells, Magnification: 200.
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Page 7 of 17rtRT-PCR analysis to find whether the above differen-
tially expressed genes induced by IGFBP-rP1 in colon
cancer cells (SOX9, IRS1, P15, AREG, IER5L, KRT8)
were also altered in Caco2 cells during the differentia-
tion process induced by sodium butyrate. Interestingly,
consistent with the gene expression change induced by
IGFBP-rP1, downregulation of IRS1 and SOX9 were
also found during the differentiation process induced by
butyrate. Other genes expression change patterns during
the differentiation process were not in consistent with
those induced by IGFBP-rP1.
Discussion
The spatial organization of the colonic mucosa implies
that in vivo the cells normally undergo a sequence of
events which includes proliferation, differentiation,
apoptosis, and extrusion. The continuously regenerating
colonic epithelium is characterized by the proliferation
of undifferentiated multipotent stem cells located at the
base of the crypts and by shedding of mature fully dif-
ferentiated cells at the luminal surface. It is during this
translocation that differentiation occurs. Thus, to iden-
tify the differentiation associated function of IGFBP-rP1
in vivo, it was of interest to determine the localization
of IGFBP-rP1-expressing cells in normal colonic epithe-
l i u m .W eh e r ef i r s tr e p o r t e dt h a tI G F B P - r P 1e x p r e s s e s
specifically in the well-differentiated cells on the surface
throughout the length of the intestine, strikingly
matches the expression pattern of the differentiation
marker of colon epithelium. Interestingly, IGFBP-rP1
expression is also well maintained and actually increased
in colorectal cancer, when compared with the paired
normal tissues, consistent with our previous study
which performed in another collection of colon cancer
samples (n = 78) [35]. The discrepancy of up regulation
of IGFBP-rP1 in colon cancer tissue and low expression
RKO SW620 CW2
bl ev rp bl ev rp bl ev rp
CDX2 38kD
CEA 180kD
Actin
Actin
bl    ev     rp           bl   ev      rp            bl   ev    rp
bl   ev    rp           bl   ev   rp           bl   ev   rp
RKO                   SW620                 CW2
RKO                      SW620                    CW2 A
B
Figure 3 Well known differentiation marker analysis after IGFBP-rP1 transfection. The experiments were conducted in three colon cancer
cell lines: RKO, SW620, CW2. The parental blank cells (-bl), PcDNA3.1 empty vector transfectants (-ev), and PcDNA3.1(IGFBP-rP1) transfectants (-rp),
were cultured in DMEM medium. A:Total cell lysates and supernatants were harvested and assayed for alkaline phosphatase activity assessing.
Results represent the mean (± SD) of three experiments.*p < 0.05. B. Total cell lysates were harvested and assayed for CEA, CDX2 expression.
Also shown are the corresponding reprobings of these blots with actin as a loading control. This blot is representative of those obtained when
the experiment was performed six times.
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by the microenvironment, which is now under investiga-
tion in our laboratory. The upregulation of IGFBP-rP1
in colon cancer tissue seems paradoxical to the well
defined expression of IGFBP-rP1 in terminally differen-
tiated cells at the normal intestinal surface. Colorectal
carcinoma consists of different histology types with dif-
ferentiation status, including tubular adenocarcinoma,
Figure 4 Well known differentiation marker analysis after recombinant IGFBP-rP1 stimulation. The experiments were conducted in three
colon cancer cell lines: RKO, SW620, CW2. After attachment for 24 hr, the cells were then stimulated with (-pr, for RKO cells, 10 μg/ml, For
SW620 and CW2 cells, 4 μg/ml) or without recombinant IGFBP-rP1 protein (-bl) in medium without FBS. Forty-eight hours after IGFBP-rP1
addition, expression of differentiation markers were performed in the cell lysates and supernatants. A:Total cell lysates and supernatants were
harvested and assayed for AKP activity assessing. Results represent the mean (± SD) of three experiments.*p < 0.05. B. Total cell lysates were
harvested and assayed for CEA, CDX2 expression. Also shown are the corresponding reprobings of these blots with actin as a loading control.
This blot is representative of those obtained when the experiment was performed six times.
Figure 5 Hierarchical clustering from six samples, based on the differentially expressed 115 probesets. RNA samples from three
independent biological replicate studies of RKO cells transfected with either PcDNA3.1(IGFBP-rP1) (three single cell clones, named RP5, RP6, RP7)
or with either empty vector control (three single cell clones, named as EV5, EV6, EV7) were labeled and hybridized to Affymetrix U133 plus 2.0
GeneChips. Gene expression data were analyzed with GCOS1.2. One hundred and fifteen differentially expressed probesets according to a signal
intensity cutoff protocol described in the text were selected for hierarchical clustering using GeneSpring 7.2. Genes with similar expression
profiles were grouped together and the resulting gene tree is shown. Strong replicate clustering was shown. The left three lines mean the
results in EV 5, EV6, EV7. The right three lines mean the results inRP5, RP6, RP7. Red represents up-regulation, green represents down-regulation.
Black indicates no change. Quantitative data for the magnitude of each gene expression change, together with gene descriptions are shown in
Table 4.
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Page 9 of 17papillary carcinoma, mucinous adenocarcinoma, signet
ring cell carcinoma, and undifferentiated carcinoma.
The differentiation status of cancer can provide insights
into the degree of malignancy, prognosis. We found that
IGFBP-rP1 was strongly expressed in low grade colorec-
tal carcinoma and weakly expressed in high grade
colorectal carcinoma, indicating that the molecule is a
potential differentiation-associated marker in colon
cancer.
Differentiation characteristics of the colon epithelium
include the emergence of a polarized morphology and
the appearance of or a significant increase in brush
Table 4 Seventy-eight reproducible differentially expressed genes induced by IGFBP-rP1 in RKO cells
the cytoskeleton and actin binding Nuclear transcription
[NM_004342] CALD1 (1, 1.4, 0.7) * [NM_024496] C14orf4 (-0.3,0.1(NC),-0.3)
[NM_001457] FLNB (0.4,1.4,-0.3) [NM_032883] C20orf100 (-0.8,-0.2(NC),-0.6)
[NM_018027] FRMD4A (0.5,0.6,0.5) * [NM_001964] EGR1 (0.7,0.4,-0.1)
[NM_005556] KRT7 (-0.2,-0.3,-0.2 (NC**)) [NM_012081] ELL2,(0.2,-0.6,-1.1)
[NM_002273] KRT8(-0.7,-0.3 (NC),-1) [NM_005252] FOS (1.1,0.6,-0.5)
[NM_002281] KRTHB1 (-3.8,0.7,-1.3) [NM_017445] H2BFS (0.5,0.7,0)
[NM_002628] PFN2 (0.3,-0.7,-0.8) [NM_080593] HIST1H2BK (0.5,0.6,-0.1(NC))
[NM_006950] SYN1 (-1.7,-1.5,-2.7) * [NM_002165] ID1 (-1.2,-1.2,-1) *
[NM_001001522] TAGLN (1,1.6,0.6) * [NM_002167] ID3 (-0.3(NC),-0.9,-0.7)
Extracellular related [NM_014903] NAV3 (0.9,0.4,0.6) *
[NM_001657] AREG (-2.7,-1.6,-0.4) * [NM_002135] NR4A1 (0.6,0.9,-0.6 (NC))
[NM_004406] DMBT1 (0.5,-1.4,-1) [NM_006186] NR4A2 (0.4,1,-0.4)
[NM_006851] GLIPR1 (0.3,0.1,0) [NM_003489] NRIP1 (-0.9,0.4, -0.3)
[NM_001553] IGFBP-rP1 (6.6,5.6,5.9) * [NM_005902] SMAD3 (-0.5,0.1,-0.6)
[NM_003155] STC1 (-2.7,-3.8,-1.5) * [NM_001005176] SP140 (1.1,1.3,0.6) *
[NM_003236] TGFA (-0.3, -0.5, -0.5) [NM_006022] TSC22D1 (-0.3(NC), -0.6,-0.5)
[NM_003254] TIMP1 (-0.1(NC),-0.3, -0.6) [NM_024836]ZNF672 (0.5,0.9,-0.1(NC))
[NM_003255] TIMP2 (-4.5,-0.3 (NC),-1) Others
[NM_022164] TINAGL1 (-0.9,0.9,-0.4) [NM_032744] C6orf105 (-5 (NC),-1.5,-2.3)
Cell proliferation and differentiation [Hs.569345]C14orf34 (1.3,1.6,0.1(NC))
[NM_000700] ANNEXIN A1 (-1.8,-1.2.-0.5(NC)) [NM_005127] CLEC2B (0.9,1.3,0.4(NC))
[NM_004936] CDKN2B (-0.8,-1.7, -0.8) * [NM_001004023] DYRK3 (0.8,0.9,-0.3(NC))
[NM_018482] DDEF1 (0.3,0.6,0.1(NC)) [NM_001008493] ENAH (0.4,0.4,0.1(NC))
[NM_015675] GADD45B (1.1,0.8,0.2 (NC)) [NM_001005915] ERBB3 (-0.8,0.2(NC),-0.4)
[NM_003641] IFITM1(-0.7,-1.5,-0.4 (NC)) [NM_005330] HBE1 (4.3,-4.6,-1.5)
[NM_001025242] IRAK1 (-0.6 (NC), -1.5,-0.6) [NM_005525] HSD11B1 (-3.1,-1.1,1.7)
[NM_014330] PPP1R15A (0.7,0.5, -0.2) [NM_203434] IER5L (-0.7,-0.7,-0.7) *
[NM_173354] SNF1LK (-0.5,-0.2,0.5) [NM_005544] IRS1 (-1.4,-0.7,-0.9) *
[NM_000346] SOX9 (-1.9,-1.5,-1.1) * [NM_002288] LAIR2 (-0.9,-1.3,0.4)
[NM_002354] TACSTD1 (-0.7,-1.4,-1.9) * [NM_002291] LAMB1 (-1.1,-0.6,-1) *
Enzyme regulated [NM_006669] LILRB1(-1.5,-1.2,-0.1 (NC))
[NM_004753] DHRS3 (-2.4,0.1 (NC),-1.6) [NM_021070] LTBP3 (-1.1,0.5(NC),-0.6)
[NM_001005336] DNM1 (-0.6,-0.4,-0.3(NC)) [NM_138794] LYPLAL1 (0.4,0.4,-0.3(NC))
[NM_005261] GEM (0.8,0.5,0.1 (NC)) [NM_024979] MCF2L (-0.1(NC),-2.6,-3.8)
[NM_015590] GPATCH4 (0.3,0.4,-0.1(NC)) [NM_006818] MLLT11 (1,-1.4,-1)
[NM_003979] GPRC5A (-1.2,-0.1,-0.7) [NM_176870] MT1K (-0.5,-0.2(NC),-0.6)
[NM_004637] RAB7 (0.5,0.5,-0.2) [NM_000271] NPC1 (0.6,0.8,0.1)
[NM_002890] RASA1 (0.3,-0.4,-0.5) [NM_002599] PDE2A (-2(NC),-1.7,-2.4)
[NM_007211] RASSF8 (0.4(MI***),1.9,2.5) [NM_018444] PPM2C (-0.6,-0.5,0.2(NC))
[NM_005168] RND3 (1,0.7, 0.1(NC)) [NM_004155] SERPINB9 (-0.6,0.3 (NC),-0.9)
[NM_005415] SLC20A1 (0.2(NC), -0.3,-0.5)
[NM_003364] UPP1(0.4,1,0.1(NC))
Numbers in parentheses are signal log ratio(log2fold change) in three clones, respectively. Positive number indicates up-regulation in IGFBP-rP1-RKO transfectants
vs empty vector-RKO transfectants, whereas negative number indicates down-regulation in IGFBP-rP1-RKO transfectants vs empty vector-RKO transfectants.
*genes reproducible in 3 clones; **NC: no change or great interruption; ***MI: Marginal Increase.
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Page 10 of 17border hydrola enzyme activities, such as AKP [36,37].
In this study, we choose the three colon cancer cell
lines without endogenous IGFBP-rP1 expression, RKO,
S W 6 2 0a n dC W 2c e l ll i n e s ,t oo b s e r v et h et r a n s f e c t i o n
of IGFBP-rP1 cDNA on the differentiation status of the
cells. RKO and CW2 cell lines are both derived from
primary colon adenocarcinoma. SW620 cell line was
initiated from a lymph node metastasis from the pri-
mary colon adenocarcinoma. We found that transfection
of IGFBP-rP1 cDNA could induce the cells to a more
pronounced anterior-posterior polarity morphology,
accompanied by the increase of AKP activity both in the
cell lysates and cell supernatants.
Interestingly, analysis of other well known colon
epithelium differentiation markers showed cell type spe-
cificity. CEA, a tumor-associated antigen, is widely used
serum biomarker for colorectal cancer. Interestingly, it
has also been shown to correlate with the differentiation
state of colon. In the normal colonic mucosa, CEA
expression showed crypt-surface distribution. CEA
expression was strong in surface epithelial cells and gob-
let cells of the upper crypts, while very weak in the mid
crypt and at the base[38]. Cell lines with high expression
of CEA showed shuttle-shape morphologic changes with
long or dendritic-like cytoplasmic processes, decreased
cell growth and de novo tumor formation in nude mice
Figure 6 Directed Acyclic Graph (DAG) of the enriched GO categories. The 115 gene probe sets differentially induced by IGFBP-rP1 were
put to the gene ontology analysis. Shown is the result of DAG analysis, a directed graph with no directed cycles. The graph showed the
significance of differently expressed genes and more specifically, the gene ontology terms present in numbers that are above random chance. P
< 0.01 and at least 2 genes (which are colored red) and their non-enriched parents (which are colored black).
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Page 11 of 17xenograft. In colon cancer cell lines, it is also widely
used as differentiation marker[39-43]. In our study,
upregulated expression of CEA were induced by IGFBP-
rP1 in SW620 and CW2 cells. No detectable expression
of CEA induced by IGFBP-rP1 in RKO cells was
observed. These findings suggested that the function of
IGFBP-rP1 in regulating cell differentiation may be cell
lineage specific. RKO cell line is a poorly differentiated
colon carcinoma cell line developed by Michael Brattain.
The AKP activity in RKO cells was lower than that of
SW620 and CW2 cells. Although the AKP activity of
PcDNA3.1(IGFBP-rP1)-RKO transfectants was higher
than that of RKO cells, it was lower than that of
PcDNA3.1(IGFBP-rP1)-SW620 and PcDNA3.1(IGFBP-
rP1)-CW2 cells. Thus, the differentiation status may
lower in RKO cells than in SW620 and CW2 cells. This
may be could explain, at least in part, why the other
well known differentiation marker such as CEA, could
not be detected after IGFBP-rP1 transfection in RKO
cells.
Interestingly, our findings were in consistent with the
studies reported by Sprenger et al., which demonstrated
the elongated appearance of high IGFBP-rP1 expressing
clones in prostate cancer cells [14]. The authors
explained that the morphological change was correlated
with an increased sensitivity to undergo apoptosis. How-
ever, based on our findings which showed the cell mor-
phological change was associated with regulations of
several epithelium differentiation associated markers, we
thought that the morphological change was tightly asso-
ciated with the differentiation induction process.
IGFBP-rP1 is a protein with secretary character. We
observed that recombinant IGFBP-rP1 stimulation could
mimic the effects of the transfection of IGFBP-rP1
cDNA, although the extent may not be as high. These
findings indicated that the autocrine stimulation was
part of the mechanism for the secretary protein. Other
mechanisms may also be responsible for the biological
behaviour of IGFBP-rP1.
Normal cells differentiate to gain in the properties
required for organ or tissue functions. However, the dif-
ferentiation program can be distorted. Malignant cells
have a differentiation block that results in an accumula-
tion of inappropriate or abnormal cell type (i.e., anapla-
sia). However, this process could partly be reversed.
Colon cancer cells undergo terminal differentiation in
response to diverse differentiation stimuli. It has been
well demonstrated that sodium butyrate, the natural
Figure 7 Verification of selected microarray results by rtRT-PCR. The 16 reproducible differentially-expressed genes in 3 clones induced by
IGFBP-rP1 in RKO cells and the differentially-expressed cytoskeleton associated genes keratin 7, keratin 8, profilin2 analysed by chip were
selected for rtRT-PCR validation. RtRT-PCR was performed on RNA extracted from IGFBP-rP1-RKO transfectants and the control cells. Delta-delta Ct
method was used to calculate relative fold changes normalized against the GAPDH gene. The relative fold change for IGFBP-rP1 from rtRT-PCR is
2.1 × 10
6. Results represent the mean (± SD) of six experiments.
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Page 12 of 17product of intestinal flora, is an typical inducer of colon
cancer cell line to terminally differentiated cells
(reviewed in [44]). Exposure to sodium butyrate induces
morphological and biochemical changes consistent with
a more differentiated state. One of these cell lines,
namely Caco2, has been extensive used and character-
ized for its ability to differentiate under sodium butyrate
stimulation[45]. In our study, the upregulation of AKP
activity and CEA expression confirmed the differentia-
tion process, although the elongated polarity morphol-
o g yc h a n g ew a sn o to b s e r v e dd u r i n gt h ep r o c e s s .
Different from the above RKO, SW620, and CW2 cells,
Caco2 cells express endogenous IGFBP-rP1. Interest-
ingly, upregulated expression of IGFBP-rP1 was detected
during the differentiation process, which showed a good
correlation with the most widely used differentiation
marker AKP activity, again indicating IGFBP-rP1 a
molecule associated with colon cancer differentiation
CDX2 is a key molecule for directing intestinal devel-
opment and differentiation. A gradient of CDX2 expres-
sion formed in the crypt-villus axis, primarily in the
villus[46]. Overexpression of CDX2 leads to growth
arrest accompanied by upregulation of several markers
associated with intestinal differentiation[47,48].
Decreased or absent expression of CDX2 were found in
poorly differentiated colon carcinomas[49-51]. In colon
cancer cell lines, it is also used as differentiation marker
[52]. We analyzed the expression of CDX2 during the
differentiation process. Interestingly, downregulation of
CDX2 induced by butyrate treatment in Caco2 cells was
found. The RKO cells showed a slight but reproducible
decrease (when performed six times) in levels of CDX2.
While the SW620 and CW2 cells showed no detectable
regulation on the CDX2 expression after transfection of
IGFBP-rP1 cDNA, suggesting that restoration of CDX2
is not required for differentiation in these cell lines. Our
findings were consistent with the studies of Oualtrough
et al [53]. In their study, no significant regulation of
CDX2 was observed with the differentiation process in
colon cell lines. No detectable gradient CDX2 expres-
sion along the axis of the crypt was found. These obser-
vations indicated that the differentiation associated
function of CDX2 may act depend upon the cell type
and may confer tissue specificity.
The studies presented here in vitro and in vivo
demonstrated that IGFBP-rP1 was a potential molecule
associated with colon epithelium cells differentiation,
expanded the previous findings on the molecule’s
Figure 8 Verification of the differentially expressed genes in SW620-IGFBP-rP1 transfectants and CW2-IGFBP-rP1 transfectants.T h e
expression of the 16 reproducible genes in 3 clones and the differentially-expressed cytoskeleton associated genes keratin 7, keratin 8, profilin2
analysed by chip were also analysed by rtRT-PCR in IGFBP-rP1-SW620 and IGFBP-rP1-CW2 transfectants versus empty vector control cells. RtRT-
PCR was performed on RNA extracted from the transfectants and the control cells. Delta-delta Ct method was used to calculate relative fold
changes normalized against the GAPDH gene. Results represent the mean (± SD) of six experiments.
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Page 13 of 17proliferation inhibition, apoptosis and senescence induc-
tion role. Based on different assumptions, several oppo-
site models linking proliferation, cell death, and
differentiation are currently coexisting [54]. Cellular
proliferation, differentiation, apoptosis and senescence
are physiological processes that show overlapping prop-
erties [55-57]. Furthermore, several lines of evidence
suggested that they are alternative, independent phe-
nomena [58,59]. The balance among proliferation, differ-
entiation, senescence and apoptosis tightly regulated to
maintain homeostasis of colon epithelium. Our findings
extend our knowledge on IGFBP-rP1’sr o l ei nt h i s
balance.
In this context, it is important to precisely identify the
molecular signature for IGFBP-rP1 in colon cancer.
Among the 78 reproducible differentially expressed
genes identified, there were several genes whose altered
expression induced by IGFBP-rP1 has been previously
reported in prostate cancer cells by sprenger et al [32],
such as IL8, KRT8. However, interestingly, SOX9 was
found to be upregulated in IGFBP-rP1-transfected pros-
tate cancer cells, while downregulated in IGFBP-rP1
transfected colon cancer cells, indicating the cell lineage
specific regulation. DAG of the enriched GO categories
demonstrated that the enzyme regulator activity genes
together with cytoskeleton and actin binding genes were
of great significance. The enzyme activity participated in
many biomedical processes. The relation between the
cytoskeleton and the differentiation process has been
well demonstrated in different organ systems[60]. Our
findings provide a clue for IGFBP-rP1’s possible func-
tion in these important biomedical processes. The upre-
guation of TAGLN and downregulation of SOX9, IRS1,
P15, AREG, IER5L, KRT8 in RKO, SW620 and CW2
colon cancer cells indicated these genes may be the tar-
get molecules for the biological behaviour of IGFBP-rP1
Control Butyrate
CEA 180kD
CDX2 38kD
Actin
AB
E
C
D
Control Butyrate
F
Figure 9 Gene expression changes during differentiation induced by butyrate in Caco2 cells. Caco2 cells were seeded into 60-mm culture
dishes at 3 × 10
5 cells/plate. After 24 hr, cells were cultured in 4 mmol/L sodium butyrate for additional 24 hr, 48 hr, 72 hr. Results are averages
of triplicate determinations. A. Total cell lysates with (72 hr point) or without butyrate stimulation were harvested and assayed for AKP activity
assessing. Results represent the mean (± SD) of three experiments.*,**p < 0.05. B. Total cell lysates with (72 hr point) or without butyrate
stimulation were harvested and assayed for CEA, CDX2 expression Also shown are the corresponding reprobings of these blots with actin as a
loading control. This blot is representative of those obtained when the experiment was performed six times. C. Phase-contrast micrographs of
cells with (72 hr point) or without butyrate stimulation were photographed. D. IGFBP-rP1 level analyzed by ELISA assay with (72 hr point)or
without butyrate stimulation *P < 0.05. E. The relationship between AKP activity and the IGFBP-rP1 level during the sodium butyrate stimulation
process. The correlation coefficient (r) = 0.945, P = 0.028. F. rtRT-PCR analysis of the IGFBP-rP1 induced differentially expressed genes (AREG, KRT8,
P15, IER5L, IRS1, SOX9, TAGLN) in Caco2 cells with or without butyrate stimulation.
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Page 14 of 17in colon cancer. The sodium butyrate induced Caco2
differentiation process was accompanied by downregula-
tion of IRS1 and SOX9. While other IGFBP-rP1 respon-
sible genes exhibited different expression patterns via
induction by sodium butyrate. It has been demonstrated
that sodium butyrate induce cellular growth arrest, dif-
ferentiation and apoptosis in colon cancer cells through
various molecular mechanisms, including histone hyper-
acetylating [61,62], nuclear factor kappaB (NF-kB) acti-
vation together with a defective beta1 integrin- focal
adhesion kinase (FAK)- phosphatidylinositol 3’-kinase
(PI3K) pathways signaling[63], downregulating extracel-
lular signal-regulated kinase (ERK) phosphorylation [64]
and induction of cyclin D3 and p21 expression[65]. Our
findings indicated that IGFBP-rP1 possiblely worked in
different signaling pathways during the differentiation
process. Our observations are consistent with the studies
by Velcich et al. demonstrating that different inducers
(12-O-tetradecanoylphorbol-13-acetate, forskolin, and
sodium butyrate) modulate specific sets of markers in
the process of differentiation induction, suggesting var-
ious inducers seem to utilize different intracellular path-
ways for induction of differentiation [39].
Downregulation of IRS1 and SOX9 by both IGFBP-
rP1 and sodium butyrate in colon cancer cells indicated
that these two genes may play important roles in the
differentiation and apoptosis induction process in colon
epithelium. IRS1 was a docking protein for both type 1
insulin-like growth factor receptor (IGF-IR) and insulin
receptor. It is a key mediator of the actions of insulin
and IGFs, sending a mitogenic, anti-apoptotic, and anti-
differentiation signal [66,67]. IRS-1 null mice exhibit
reduced body growth and reduced growth of several
organs including the intestine [68]. Up regulation of
IRS1 were found in colon cancer, while downregulation
of IRS1 levels were found in differentiating cells [69,70].
As to SOX9, previous studies showed the role of SOX9
in committed differentiation, such as chondrocyte differ-
entiation, outer root sheath differentiation, and the for-
mation of the hair stem cell compartment. Blache and
colleagues reported that SOX9 can inhibit intestinal
crypt differentiation in the colon [71]. Contrary to the
expression pattern of IGFBP-rP1 in the healthy human
colon epithelium, our research group found that the
expression of SOX9 is restricted to the proliferative,
lower half of the crypt [72], consistent with the studies
by Bastide et al.[73]. Additional experiments demon-
strating the exact roles of these two genes in mediating
IGFBP-rP1’s effect on differentiation should be
performed.
Analysis of differentiation by tumor cells often pro-
vides valuable information for both the diagnosis and
therapy of human cancers. One can envision very excit-
ing times in the future as seeks to testing the role of
IGFBP-rP1 using the knockout mice model. Because our
current results are limited to colorectal tumorigenesis
models, other studies will be needed to determine
whether our findings apply to other organ systems.
From a clinical point of view, specifically targeting and
manipulating the function of IGFBP-rP1 may offer a
novel approach to the differentiation therapy of colon
cancer. Further experiments are under way to study the
molecular mechanism underlying the observations
reported here.
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